GXMC
TCRT icon

Global X Management Company’s Alaunos Therapeutics TCRT Stock Holding History

Global X Management Company’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed -$4K – 1227
2017
Q1 		$4K Hold
4
– – ﹤0.01% 1189
2016
Q4 		$3K Hold
4
– – ﹤0.01% 1081
2016
Q3 		$3K Hold
4
– – ﹤0.01% 1085
2016
Q2 		$3K Buy
+4
New +$4.36K ﹤0.01% 977

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Global X Management Company's TCRT Position: Q2 2017 in Review

Global X Management Company sold out of Alaunos Therapeutics (TCRT) in Q2 2017, closing a stake of 4 shares — an estimated $4K sold.

Global X Management Company first reported a position in TCRT in Q2 2016 and held it in 4 quarters. The position peaked at $4K in Q1 2017. 122 funds tracked by Wall St. Rank hold TCRT as of Q2 2017.

  • Global X Management Company reported no remaining Alaunos Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Global X Management Company sold 4 Alaunos Therapeutics shares in Q2 2017, an estimated $4K.
  • Global X Management Company first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 4 quarters.
  • Global X Management Company's Alaunos Therapeutics position peaked at $4K in Q1 2017.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2017.

Based on Global X Management Company's 13F filing for Q2 2017, filed 1 Aug 2017.